This S1 appendix provides additional information on the methodology used to carry out the analyses as well as some additional sets of results. Table 1 reports the set of explanatory variables used to calculate the propensity score (PS) and the generalized propensity score (GPS). Unless otherwise specified, explanatory variables have been coded as categorical variables. The definition and the thresholds used to define each category are reported in the column 'definitions'. Table 2 reports the full list of five criteria that were used to select the study sample used to carry out the analyses. Table 3 reports the p-values of the Kruskal-Wallis H tests to understand whether the number of office-based visits differed, based on the socio-demographic characteristics of the individuals included in the study. Table 4 reports the p-values of the Kruskal-Wallis H test (in the case of access to a healthcare service) and of the ANOVA tests (in the case of healthcare expenditure) to understand whether access to healthcare services and its related and expenditure differed, based on the number of office-based visits. Table 5 reports the outputs of the generalized linear model used to calculate the GPS. A gamma distribution with log-link was used to fit the model. The probability of use of officebased care is calculated conditional on the set of variables reported in table 1. Table 6 reports the results of the validation test used to confirm that only similar individuals are used in the calculation of the dose-response function. The test is repeated for each additional office-based visit that is provided (i.e. shifting from no use of office-based care to 1 office-based visit, shifting from 1 office-based visit to 2 office-based visits, etc.). This table reports the mean difference between the control and the intervention groups and the t-stat used to assess whether the difference is statistically significant. Figure 1 reports the graphical representation of the dose-response function and the treatment effect function (the latter is a graphical representation of the results presented in table 3 of the main paper). Results are reported for all the 11 dimensions considered in the study. In each diagram, the horizontal axis represents the number of office-based visits while the vertical axis may represent either the probability of access to a healthcare service (if the probability of access is studied) or its associated healthcare expenditure (if the expenditure is studied). The dose-response function represents the absolute probability of access to any healthcare service (or its associated expenditure) dependent on the number of office-based visits. The treatment effect function represents the effect associated to increasing use of office-based care by one additional visit. Table 7 reports the outputs of the generalized linear model used to calculate the GPS in the additional set of analyses. A gamma distribution with log-link was used to fit the model. The probability of use of office-based care is calculated conditional on the set of variables reported in table 1 supplemented by drug expenditure and outpatient expenditure. The inclusion of these two additional variables allows the matching of individuals with similar expenditure for these two healthcare services. Thus, the additional set of analyses allows the calculation of the dose-response function accounting for the potential confounding effects caused by different levels of drug and outpatient expenditure. Table 8 reports the results of the validation test used to confirm that only similar individuals are used in the calculation of the dose-response function in the additional set of analyses (i.e. those including drug expenditure and outpatient expenditure in the set of variables used to calculate the PS). The test is repeated for each additional office-based visit that is provided and the table reports the mean difference between the control and the intervention groups and the t-stat used to assess whether the difference is statistically significant. Table 9 
reports the set of explanatory variables used to calculate the propensity score (PS) and the generalized propensity score (GPS). Unless otherwise specified, explanatory variables have been coded as categorical variables. The definition and the thresholds used to define each category are reported in the column 'definitions'. Table 2 reports the full list of five criteria that were used to select the study sample used to carry out the analyses. Table 3 reports the p-values of the Kruskal-Wallis H tests to understand whether the number of office-based visits differed, based on the socio-demographic characteristics of the individuals included in the study. Table 4 reports the p-values of the Kruskal-Wallis H test (in the case of access to a healthcare service) and of the ANOVA tests (in the case of healthcare expenditure) to understand whether access to healthcare services and its related and expenditure differed, based on the number of office-based visits. Table 5 reports the outputs of the generalized linear model used to calculate the GPS. A gamma distribution with log-link was used to fit the model. The probability of use of officebased care is calculated conditional on the set of variables reported in table 1. Table 6 reports the results of the validation test used to confirm that only similar individuals are used in the calculation of the dose-response function. The test is repeated for each additional office-based visit that is provided (i.e. shifting from no use of office-based care to 1 office-based visit, shifting from 1 office-based visit to 2 office-based visits, etc.). This table reports the mean difference between the control and the intervention groups and the t-stat used to assess whether the difference is statistically significant. Figure 1 reports the graphical representation of the dose-response function and the treatment effect function (the latter is a graphical representation of the results presented in table 3 of the main paper). Results are reported for all the 11 dimensions considered in the study. In each diagram, the horizontal axis represents the number of office-based visits while the vertical axis may represent either the probability of access to a healthcare service (if the probability of access is studied) or its associated healthcare expenditure (if the expenditure is studied). The dose-response function represents the absolute probability of access to any healthcare service (or its associated expenditure) dependent on the number of office-based visits. The treatment effect function represents the effect associated to increasing use of office-based care by one additional visit. Table 7 reports the outputs of the generalized linear model used to calculate the GPS in the additional set of analyses. A gamma distribution with log-link was used to fit the model. The probability of use of office-based care is calculated conditional on the set of variables reported in table 1 supplemented by drug expenditure and outpatient expenditure. The inclusion of these two additional variables allows the matching of individuals with similar expenditure for these two healthcare services. Thus, the additional set of analyses allows the calculation of the dose-response function accounting for the potential confounding effects caused by different levels of drug and outpatient expenditure. Table 8 reports the results of the validation test used to confirm that only similar individuals are used in the calculation of the dose-response function in the additional set of analyses (i.e. those including drug expenditure and outpatient expenditure in the set of variables used to calculate the PS). The test is repeated for each additional office-based visit that is provided and the table reports the mean difference between the control and the intervention groups and the t-stat used to assess whether the difference is statistically significant. Table 9 reports the dose-response effect on the use of inpatient care, its associated expenditure and total healthcare expenditure for diabetes by number of office-based visits in the additional set of analyses. The dose-response effects are calculated only on individuals that have been matched by the set of variables reported in table 1 supplemented by drug expenditure and outpatient expenditure. in table 7 of this S1 appendix. Results are reported for a limited set of dimensions including: probability of access to inpatient care, expenditure for inpatient care and total healthcare expenditure for diabetes. Guidance on interpreting the results can be found in the note to figure 1. The dose-response effects are calculated only on individuals that have been matched by the set of variables reported in table 1. The selection criteria to include a patient in the sample were relaxed to include use of inpatient care services and total expenditure for any diagnosis (as opposed to the analyses presented in table 3 of the paper that focused only on diabetes, i.e. ICD-9-CM code of 250 and subcategories). Figure 3 reports the dose response functions and treatment effect functions for studied outcomes. The treatment effect function is a graphical representation of the results reported in table 8 of this S1 appendix. Results are reported for a limited set of dimensions including: probability of access to inpatient care, expenditure for inpatient care and total healthcare expenditure for diabetes. Guidance on interpreting the results can be found in the explanation to figure 1. 4 1997-2000, 2001-2004, 2005-2008, 2009-2012 Note: BMI stands for body-mass index 
